Conventional versus reverse sequence of neoadjuvant epirubicin/cyclophosphamide and docetaxel: sequencing results from ABCSG-34.

Rupert BartschChristian F SingerGeorg PfeilerMichael HubalekHerbert StoegerAngelika PichlerEdgar PetruVesna Bjelic-RadisicRichard GreilMargaretha RudasTea Maria Muy-KhengViktor WetteAndreas L PetzerPaul SeveldaDaniel EglePeter C DubskyMartin FilipitsFlorian FitzalRuth ExnerRaimund JakeszMarija BalićChristoph TinchonZsuzsanna Bago-HorvathSophie FrantalMichael Gnantnull null

Published in: British journal of cancer (2021)

Upfront docetaxel did not improve chemotherapy activity or tolerability; these results suggest that upfront neoadjuvant treatment with anthracyclines remains a valid option.

Keyphrases

locally advanced
rectal cancer
squamous cell carcinoma
radiation therapy
lymph node
low dose
single cell
high dose
randomized controlled trial
combination therapy
early breast cancer